Your browser doesn't support javascript.
loading
[Transurethral plasma resection of the prostate for acute urinary retention in patients with advanced prostate cancer].
Pang, Kun; Liang, Qing; Chen, Bo; Shi, Zhen-Duo; Dong, Yang; Han, Cong-Hui.
  • Pang K; Department of Urology, Xuzhou Central Hospital / Xuzhou School of Clinical Medicine, Xuzhou Medical University, Xuzhou, Jiangsu 221009, China.
  • Liang Q; Department of Urology, Xuzhou Central Hospital / Xuzhou School of Clinical Medicine, Xuzhou Medical University, Xuzhou, Jiangsu 221009, China.
  • Chen B; Department of Urology, Xuzhou Central Hospital / Xuzhou School of Clinical Medicine, Xuzhou Medical University, Xuzhou, Jiangsu 221009, China.
  • Shi ZD; Department of Urology, Xuzhou Central Hospital / Xuzhou School of Clinical Medicine, Xuzhou Medical University, Xuzhou, Jiangsu 221009, China.
  • Dong Y; Department of Urology, Xuzhou Central Hospital / Xuzhou School of Clinical Medicine, Xuzhou Medical University, Xuzhou, Jiangsu 221009, China.
  • Han CH; Department of Urology, Xuzhou Central Hospital / Xuzhou School of Clinical Medicine, Xuzhou Medical University, Xuzhou, Jiangsu 221009, China.
Zhonghua Nan Ke Xue ; 29(1): 25-30, 2023 Jan.
Article en Zh | MEDLINE | ID: mdl-37846828
ABSTRACT

OBJECTIVE:

To compare the safety of transurethral plasma resection of the prostate (TuPkRP) in the treatment of advanced PCa (APC)-related acute urinary retention (AUR) with that in the treatment of BPH-related AUR and investigate the oncologic characteristics of the PCa patient after TuPkRP.

METHODS:

In this retrospective study, we first compared the baseline data between the patients with APC-related AUR (group A, n = 32) and those with BPH-related AUR (group B, n = 45) as well as their surgical parameters, such as the operation time, pre- and post-operative hemoglobin levels, IPSS at 3 months after TuPkRP and length of postoperative hospital stay. Then, we observed possible TuPkRP-induced tumor progression by comparing the oncologic parameters, such as the PSA level and ECT-manifested bone metastasis, between the APC-AUR patients treated by androgen-deprivation therapy (ADT) + TuPkRP and those treated by ADT only (group C, n = 24).

RESULTS:

There were no statistically significant differences in the baseline data between the APC-AUR and BPH-AUR patients (P > 0.05). The operation time and postoperative hospital stay were significantly longer in the APC-AUR than in the BPH-AUR group (P < 0.05), but the decreases in the hemoglobin level and IPSS at 3 months after operation showed no significant differences between the two groups of patients (P > 0.05). Besides, no statistically significant differences were observed in the oncologic parameters between the APC-AUR patients treated by ADT + TuPkRP and those by ADT only (P > 0.05).

CONCLUSION:

The safety of TuPkRP was not significantly lower and the rates of postoperative complications and adverse events were not significantly higher in the patients with APC-related AUR than in those with BPH-related AUR. And this surgical strategy did not significantly improve the progression of APC.
Asunto(s)
Palabras clave
Search on Google
Banco de datos: MEDLINE Asunto principal: Hiperplasia Prostática / Neoplasias de la Próstata / Retención Urinaria / Resección Transuretral de la Próstata Límite: Humans / Male Idioma: Zh Año: 2023 Tipo del documento: Article
Search on Google
Banco de datos: MEDLINE Asunto principal: Hiperplasia Prostática / Neoplasias de la Próstata / Retención Urinaria / Resección Transuretral de la Próstata Límite: Humans / Male Idioma: Zh Año: 2023 Tipo del documento: Article